SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    David R. Gastfriend, A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders, Annals of the New York Academy of Sciences, 2014, 1327, 1
  2. 2
    Ali Keshtkaran, Alireza Mirahmadizadeh, Alireza Heidari, Mehdi Javanbakht, Cost-effectiveness of Methadone Maintenance Treatment in Prevention of HIV Among Drug Users in Shiraz, South of Iran, Iranian Red Crescent Medical Journal, 2014, 16, 1

    CrossRef

  3. 3
    Chih Yin Hsiao, Kao Chin Chen, Lan-Ting Lee, Hsin Chun Tsai, Wei Hung Chang, I Hui Lee, Po See Chen, Ru-Band Lu, Yen Kuang Yang, The reductions in monetary cost and gains in productivity with methadone maintenance treatment: One year follow-up, Psychiatry Research, 2014,

    CrossRef

  4. 4
    Bach Xuan Tran, Long Thanh Nguyen, Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS, International Journal of Drug Policy, 2013, 24, 6, e105

    CrossRef

  5. 5
    Shih-Hsien Lin, Kao Chin Chen, Sheng-Yu Lee, Chih-Yin Hsiao, I Hui Lee, Tzung Lieh Yeh, Po See Chen, Ru-Band Lu, Yen Kuang Yang, The economic cost of heroin dependency and quality of life among heroin users in Taiwan, Psychiatry Research, 2013, 209, 3, 512

    CrossRef

  6. 6
    Michael Sonntag, Hans-Helmut König, Alexander Konnopka, The Estimation of Utility Weights in Cost-Utility Analysis for Mental Disorders: A Systematic Review, PharmacoEconomics, 2013, 31, 12, 1131

    CrossRef

  7. 7
    M. Ben Khelil, A. Tracqui, C. Jamey, B. Ludes, Intoxications mortelles aux opiacés/opioïdes expertisées dans le laboratoire de toxicologie médico-légale de l’IML de Strasbourg durant la période 2000–2009, La Revue de Médecine Légale, 2012, 3, 1, 19

    CrossRef

  8. 8
    Gregory S. Zaric, Andrew W. Brennan, Michael Varenbut, Jeff M. Daiter, The Cost of Providing Methadone Maintenance Treatment in Ontario, Canada, The American Journal of Drug and Alcohol Abuse, 2012, 38, 6, 559

    CrossRef

  9. 9
    Gerardo González, Mauricio Romero-González, Alternativas farmacológicas para el tratamiento de la dependencia a la heroína: un nuevo reto en Colombia, Revista Colombiana de Psiquiatría, 2010, 39, 188S

    CrossRef

  10. 10
    Dennis McCarty, Nancy A. Perrin, Carla A. Green, Michael R. Polen, Michael C. Leo, Frances Lynch, Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan, Drug and Alcohol Dependence, 2010, 111, 3, 235

    CrossRef

  11. 11
    Phillip Oliver, Jenny Keen, Georgina Rowse, Elizabeth Ewins, Laura Griffiths, Nigel Mathers, The effect of time spent in treatment and dropout status on rates of convictions, cautions and imprisonment over 5 years in a primary care-led methadone maintenance service, Addiction, 2010, 105, 4
  12. 12
    Emlyn S. Jones, Brent A. Moore, Jody L. Sindelar, Patrick G. O’Connor, Richard S. Schottenfeld, David A. Fiellin, Cost analysis of clinic and office-based treatment of opioid dependence: Results with methadone and buprenorphine in clinically stable patients, Drug and Alcohol Dependence, 2009, 99, 1-3, 132

    CrossRef

  13. 13
    Margaret L. Brandeau, Gregory S. Zaric, Optimal investment in HIV prevention programs: more is not always better, Health Care Management Science, 2009, 12, 1, 27

    CrossRef

  14. 14
    Marian Shanahan, Richard Mattick, Pharmacotherapies for the Treatment of Opioid Dependence, 2009,

    CrossRef

  15. 15
    Christopher M Doran, Economic Evaluation of Interventions to Treat Opiate Dependence, PharmacoEconomics, 2008, 26, 5, 371

    CrossRef

  16. 16
    Michael Soyka, Christina Zingg, Gabriele Koller, Heinrich Kuefner, Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study, The International Journal of Neuropsychopharmacology, 2008, 11, 05

    CrossRef

  17. 17
    Anirban Basu, A. David Paltiel, Harold A. Pollack, Social costs of robbery and the cost-effectiveness of substance abuse treatment, Health Economics, 2008, 17, 8
  18. 18
    David A. Highfield, Robert P. Schwartz, Jerome H. Jaffe, Kevin E. O'Grady, Intravenous and intranasal heroin-dependent treatment-seekers: characteristics and treatment outcome, Addiction, 2007, 102, 11
  19. 19
    Greg Scott, Sandra D. Thomas, Harold A. Pollack, Bradley Ray, Observed Patterns of Illicit Opiate Overdose Deaths in Chicago, 1999–2003, Journal of Urban Health, 2007, 84, 2, 292

    CrossRef

  20. 20
    Jason M White, Olga V Lopatko, Opioid maintenance: a comparative review of pharmacological strategies, Expert Opinion on Pharmacotherapy, 2007, 8, 1, 1

    CrossRef

  21. 21
    M. P. Carrieri, L. Amass, G. M. Lucas, D. Vlahov, A. Wodak, G. E. Woody, Buprenorphine Use: The International Experience, Clinical Infectious Diseases, 2006, 43, Supplement 4, S197

    CrossRef

  22. 22
    Christopher M Doran, Marian Shanahan, Erol Digiusto, Susannah O’Brien, Richard P Mattick, Cost-effectiveness analysis of maintenance agonist treatments in the NEPOD, Expert Review of Pharmacoeconomics & Outcomes Research, 2006, 6, 4, 437

    CrossRef

  23. 23
    Giedrius Vanagas, Zilvinas Padaiga, Eugenijus Bagdonas, Cost-Utility Analysis of Methadone Maintenance Treatment: A Methodological Approach, Substance Use & Misuse, 2006, 41, 1, 87

    CrossRef

  24. 24
    Harold A. Pollack, Thomas D'Aunno, Barbara Lamar, Outpatient substance abuse treatment and HIV prevention: An update, Journal of Substance Abuse Treatment, 2006, 30, 1, 39

    CrossRef

  25. 25
    John W. Davison, Marie L. Sweeney, Kristen R. Bush, Tania M. Davis Correale, Donald A. Calsyn, Joseph P. Reoux, Kevin L. Sloan, Daniel R. Kivlahan, Outpatient Treatment Engagement and Abstinence Rates Following Inpatient Opioid Detoxification, Journal of Addictive Diseases, 2006, 25, 4, 27

    CrossRef

  26. 26
    Marian Shanahan, Alys Havard, Maree Teesson, Katherine Mills, Anna Williamson, Joanne Ross, Patterns and costs of treatment for heroin dependence over 12 months: fndings from the Australian Treatment Outcome Study, Australian and New Zealand Journal of Public Health, 2006, 30, 4
  27. 27
    Steven Simoens, Anne Ludbrook, Catriona Matheson, Christine Bond, Pharmaco-economics of community maintenance for opiate dependence: A review of evidence and methodology, Drug and Alcohol Dependence, 2006, 84, 1, 28

    CrossRef

  28. 28
    Michael T. French, Michael Drummond, A research agenda for economic evaluation of substance abuse services, Journal of Substance Abuse Treatment, 2005, 29, 2, 125

    CrossRef

  29. 29
    Gary A. Zarkin, Laura J. Dunlap, Katherine A. Hicks, Daniel Mamo, Benefits and costs of methadone treatment: results from a lifetime simulation model, Health Economics, 2005, 14, 11
  30. 30
    Andrew J. Saxon, Dennis McCarty, Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs, Pharmacology & Therapeutics, 2005, 108, 1, 119

    CrossRef

  31. 31
    Lynn E. Sullivan, David S. Metzger, Paul J. Fudala, David A. Fiellin, Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users, Addiction, 2005, 100, 2
  32. 32
    Mary Haack, Farrokh Alemi, Susanna Nemes, Honorable Jeri B. Cohen, Experience with Family Drug Courts in Three Cities, Substance Abuse, 2005, 25, 4, 17

    CrossRef

  33. 33
    Benedikt Fischer, Jürgen Rehm, Gregory Kim, Maritt Kirst, Eyes Wide Shut? – A Conceptual and Empirical Critique of Methadone Maintenance Treatment, European Addiction Research, 2005, 11, 1, 1

    CrossRef

  34. 34
    Gerardo Gonzalez, Alison Oliveto, Thomas R Kosten, Combating opiate dependence: a comparison among the available pharmacological options, Expert Opinion on Pharmacotherapy, 2004, 5, 4, 713

    CrossRef

  35. 35
    Carmen L. Masson, Paul G. Barnett, Karen L. Sees, Kevin L. Delucchi, Amy Rosen, Wynnie Wong, Sharon M. Hall, Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-day methadone detoxification, Addiction, 2004, 99, 6
  36. 36
    Mireia Jofre-Bonet, Jody L. Sindelar, Ismene L. Petrakis, Charla Nich, Tami Frankforter, Bruce J. Rounsaville, Kathleen M. Carroll, Cost effectiveness of disulfiram, Journal of Substance Abuse Treatment, 2004, 26, 3, 225

    CrossRef

  37. 37
    Christine Godfrey, Duncan Stewart, Michael Gossop, Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS), Addiction, 2004, 99, 6
  38. 38
    Joan Trujols, José Pérez de los Cobos, Morbimortalidad relacionada con el uso de metadona: necesidad de su contextualización, Medicina Clínica, 2004, 122, 3, 116

    CrossRef

  39. 39
    Ramin Mojtabai, Joshua Graff Zivin, Effectiveness and Cost-effectiveness of Four Treatment Modalities for Substance Disorders: A Propensity Score Analysis, Health Services Research, 2003, 38, 1p1
  40. 40
    Roy J. Goldberg, Robert Grabowski, Methadone Maintenance: Its Future in Skilled Nursing Facilities, Journal of the American Medical Directors Association, 2003, 4, 2, 98

    CrossRef

  41. 41
    Roy J. Goldberg, Robert Grabowski, Methadone Maintenance: Its Future in Skilled Nursing Facilities, Journal of the American Medical Directors Association, 2003, 4, 2, 98

    CrossRef

  42. 42
    Michael T. French, Helena J. Salomé, Jody L. Sindelar, A. Thomas McLellan, Benefit-Cost Analysis of Addiction Treatment: Methodological Guidelines and Empirical Application Using the DATCAP and ASI, Health Services Research, 2002, 37, 2
  43. 43
    Anna García-Altés, Josep Ma Ollé, Fernando Antoñanzas, Joan Colom, The social cost of illegal drug consumption in Spain, Addiction, 2002, 97, 9
  44. 44
    Gerardo Gonzalez, Alison Oliveto, Thomas R. Kosten, Treatment of Heroin (Diamorphine) Addiction, Drugs, 2002, 62, 9, 1331

    CrossRef

  45. 45
    Irene Kuo, Benedikt Fischer, David Vlahov, Consideration of a North American heroin-assisted clinical trial for the treatment of opiate-dependent individuals, International Journal of Drug Policy, 2000, 11, 5, 357

    CrossRef

  46. 46
    HIV transmission and the cost-effectiveness of methadone maintenance, American Journal of Public Health, 2000, 90, 7, 1100

    CrossRef

  47. 47
    Gregory S. Zaric, Margaret L. Brandeau, Paul G. Barnett, Methadone Maintenance and HIV Prevention: A Cost-Effectiveness Analysis, Management Science, 2000, 46, 8, 1013

    CrossRef

  48. 48
    Paul G. Barnett, The cost-effectiveness of substance abuse treatment, Current Psychiatry Reports, 1999, 1, 2, 166

    CrossRef